Ikonisys

Ikonisys Current Ratio

The Current Ratio of Ikonisys (ALIKO.PA) as of Oct 21, 2026 is 0.33. In the previous year, Current Ratio was 0.26 — a change of 28.87% (higher).

Current Ratio

0.33

YoY

28.87%

Last updated:

Current Ratio of Ikonisys is 2025 0.33 . Current Ratio of Ikonisys was 2024 0.26 . It decreases by 28.87% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ikonisys Stock analysis

What does Ikonisys do? Ikonisys SA generates revenue through the sale of its cell diagnostic products, including oncoFISH bladder, oncoFISH her2, oncoFISH cervical, oncoFISH PTEN, oncoFISH ALK, and Explorer applications. These products are designed for cancer diagnosis, genetic disorder detection, and fertility testing, utilizing advanced molecular and immunological markers. The company's target customers are healthcare providers and clinical laboratories seeking accurate rare cell detection solutions. Ikonisys SA's offerings are tailored to specific medical applications such as bladder, breast, cervical, prostate, lung, and hematological cancer diagnostics, leveraging its proprietary Ikoniscope robotic components and digital microscope technology. The firm's product portfolio focuses on specialized diagnostic applications, with oncoFISH solutions targeting specific cancer types through molecular marker analysis. Explorer applications support hematological cancer diagnostics, while the underlying technology combines image acquisition, software engine, and digital microscopy for reliable cell detection. Ikonisys SA serves the healthcare sector by providing tools that enable precise diagnosis of genetic conditions and cancer types through its unique cellular analysis platform. Ikonisys SA's revenue streams are derived from the distribution of its diagnostic applications to clinical settings. The company's products are sold to healthcare institutions requiring advanced diagnostic capabilities for cancer, genetic disorders, and fertility issues. By offering targeted solutions like oncoFISH bladder for bladder cancer and oncoFISH her2 for breast cancer, Ikonisys SA addresses specific diagnostic needs within the medical field, utilizing its proprietary technology stack including Ikoniscope components and digital microscopy. Ikonisys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ikonisys stock

Current Ratio of Ikonisys is 0.33 in 2025.

Current Ratio of Ikonisys changed from 0.26 to 0.33, representing a 28.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Ratio Ikonisys since 2006 – with annual values, charts, and detailed analysis.

The Current Ratio measures a company's ability to pay short-term obligations. A ratio above 1 indicates that current assets exceed current liabilities.

Current Ratio = Current Assets / Current Liabilities

A 'good' varies by industry and company stage. On Eulerpool, you can compare Current Ratio's Ikonisys with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Ikonisys

All Key Metrics — Ikonisys